The event gathers both patients and researchers from academia and the pharma industry to discuss widely innovative therapeutic solutions for Charcot-Marie-Tooth disease. This yearly convention enhances the scope and possibilities of research discoveries a step forward for the people who are living with CMT!
On September 17th, from 2:50 pm to 3:45 pm ET (8:50 pm to 9:45 pm CET), our CEO Dr. Sylvain Celanire will be on the panelist of the "Biopharma Activity in CMT" session. There will be a key discussion on why CMT is the next indication of interest for companies and investors.
We feel extremely thankful to CMT Research Foundation for providing such a global platform. This boosts the awareness amongst every individual who is going through CMT, and it helps us to work with that objective.